Cingulate Inc. Announces USPTO Patent for CTx-1301 Through 2042

What Happened Cingulate Inc. announced on June 16, 2026 (via Form 8-K, Item 7.01) that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 12,653,791. The Patent covers key aspects of CTx-1301’s formulation and method of use and is effective through December 2042. The company had previously reported a Notice of Allowance for this patent. A press release dated June 16, 2026 is attached as Exhibit 99.1.

Key Details

• Patent number: U.S. Patent No. 12,653,791.
• Issue/announcement date: Press release and 8-K filed June 16, 2026.
• Coverage: Key aspects of CTx-1301 formulation and method of use.
• Patent term: Through December 2042.
• Filing type: Regulation FD disclosure (Form 8-K, Item 7.01); press release attached as Exhibit 99.1.

Why It Matters This filing records an intellectual property milestone: formal USPTO issuance of a patent protecting CTx-1301’s formulation and use through December 2042. For investors, the patent is a legal protection that the company can cite when discussing CTx-1301’s development and commercialization plans. The 8-K is a disclosure of the patent issuance and does not include financial results or other business changes.